Lloyd Mitchell Segal - Jan 30, 2023 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role: President and CEO, Director
Signature: /s/ Steve Forte, Attorney-in-Fact
Stock symbol: RPTX
Transactions as of: Jan 30, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/1/2023, 08:44 PM
Previous filing: Jan 24, 2022
Next filing: Mar 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPTX	Common Shares	Award	$0	+78.6K	+1282.03%	$0.00	84.7K	Jan 30, 2023	Direct	F1, F2
holding	RPTX	Common Shares						94.5K	Jan 30, 2023	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPTX	Employee Stock Option (right to buy)	Award	$0	+344K		$0.00	344K	Jan 30, 2023	Common Shares	344K	$12.42	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of January 30, 2024, January 30, 2025 and January 30, 2026, subject to Reporting Person continuing to provide service through each such date.
F2	Includes 398 shares and 729 shares acquired on August 13, 2021 and February 15, 2022, respectively, under the Issuer's employee stock purchase plan.
F3	These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
F4	Twenty-five percent (25%) of the shares subject to the option shall vest on January 30, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.